01/2024
We are very proud to publish our press release on the research and treatment of…
01/2024
Starting 2024 with an outlook on our goals 🎯👨👩👧👦 Further build R&D organization hiring additional internal HR…
01/2024
Just in time for the start of the new year, we bring a press article…
12/2023
Our last translational advisory board of the year dealing with aspects of autologous tumor vaccine production…
12/2023
Please read a very nice article about Vaccentis in oe24.at Krebs "wegimpfen": Wird das dank neuer Forschung…
11/2023
Very interesting summary article on therapeutic cancer vaccines and their mechanisms of action. Principles of…
11/2023
Great portrait of our Head of Research & Development and CMO, Dr. Ingrid Rauter. Ingrid talks…
10/2023
Please read an article on the adjuvant treatment options in Renal Cell Carcinoma. This summary…
10/2023
On Friday, 13.10.2023, Vaccentis held an Investor Meeting in Zürich. Prof. Martin Marszalek, Department Head for…
10/2023
Vaccentis has dedicated itself to the development and production of autologous tumour vaccines.With VCC-001, the…
09/2023
On September 21st we presented the Vaccentis Business and Pipeline Plan at the Sachs Biotech Conference…
09/2023
Meet us at the 23rd Annual Biotech in Europe Forum, 20th - 21st of September…
09/2023
VCC-001 has the potential to elicitate a humoral and cell-mediated immune response. Antigen presentation takes…
03/2023
Vaccentis attends the Sachs conference and Bio Europe Spring in Basel to present the core…
08/2023
Vaccentis performs in silico antigen mapping in collaboration with bioinformatic specialists with extensive background in Oncology…